Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 231-242

  Scior, Thomas ^a   Guevara García, José Antonio ^b   Melendez, Fj ^b   Abdallah, Hassan H ^c   Do, Quoc Tuan ^d   Bernard, Philippe ^d  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b CENTRO TLAXCALA DE BIOLOGÍA DE LA CONDUCTA   (Mexico)

^c SCHOOL OF PHYSICS   (Malaysia)

^d GreenPharma SA   (France)

Author keywords

Computer assisted drug design (CADD); Diabetes; Inhibitors; Insulin; PTP1B

Indexed keywords

AMMONIUM VANADATE; BIS MALTOLATEOXOVANADATE; CAFFEINE; GLUCOSE; INSULIN; INSULIN RECEPTOR; PICOLINAMIDE DIOXOVANADATE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; TSAG 0101; UNCLASSIFIED DRUG; VANADIC ACID; VANADIUM DERIVATIVE; COORDINATION COMPOUND; ENZYME INHIBITOR; PICOLINIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; IC 50; INFRARED SPECTROSCOPY; INSULIN RELEASE; LD 50; MOUSE; NONHUMAN; PROTEIN HYDROLYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TOXICITY TESTING; ANIMAL; BIOLOGY; DRUG ANTAGONISM; DRUG EFFECT; LEWIS RAT; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS ISLET BETA CELL; SECRETION; SYNTHESIS;

ANIMALS; BLOOD GLUCOSE; COMPUTATIONAL BIOLOGY; COORDINATION COMPLEXES; ENZYME INHIBITORS; FEMALE; INSULIN; INSULIN-SECRETING CELLS; LETHAL DOSE 50; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PICOLINIC ACIDS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS; RATS, INBRED LEW;

EID: 79952113877     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S8445     Document Type: Article

References (88)

1. World Health Organization. Diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, Geneva; 1999.
2. Astrup A, Finer N. Redefining type 2 diabetes: "diabesity" or "obesity dependant diabetes mellitus". Obesity Rev. 2000;1:57-59.
3. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva; 1985.
4. Zimmet P, Alberti KGMM, Shaw J. Global and societal implication of the diabetes epidemic. Nature. 2001;414:782-787.
5. Moller DE. New drug t0061rgets for type 2 diabetes and the metabolic syndrome. Nature. 2001;414:821-827.
6. Saltiel AR, Khan CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
7. Cheng A, Dubé N, Gu F, Tremblay ML. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eu J Biochem. 2002;269(4):1050-1059.
8. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544-1548.
9. Doman TN, McGovern SL, Witherbee BJ, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem. 2002;45:2213-2221.
10. Patankar SJ, Jurs PC. Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors. J Chem Inf Comp Sci. 2003;43:885-899.
11. Shen K, Keng Y-F, Wu L, Guo X-L, Lawrence DS, Zhang Z-Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem. 2001; 276(50):47311-47319.
12. Sun J-P, Fedorov AA, Lee S-Y, et al. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J Biol Chem. 2003;278(14):12406-12414.
13. Szczepankiewicz BG, Liu G, Hajduk PJ, et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linkedfragment strategy. J Am Chem Soc. 2003;125(14):4087-4096.
14. Wang H, Lim KL, Yeo SL, et al. Isolation of a novel protein tyrosine phosphatase inhibitor, 2-methyl-fervenulone, and its precursors from Streptomyces. J Nat Prod. 2000;63(12):1641-1646.
15. Groves MR, Yao Z-J, Roller PP, Burke TRJ, Barford D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochem. 1998;37(51): 17773-17783.
16. Shechter Y, Karlish SJ. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature (Lond). 1980;284: 556-558.
17. Thompson KH, Orvig C. Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem. 2006;100:1925-1935.
18. Nxumalo F, Glover NR, Tracey AS. Kinetics and molecular modelling studies of the inhibition of protein tyrosine phosphatases by N,N-dimethylhydroxylamine complexes of vanadium(V). J Biol Inorg Chem. 1998;3:534-542.
19. Domingo JL. Vanadium: a review of the reproductive and developmental toxicity. Reprod Toxicol. 1996;10(3):175-182.
20. Ramos S, Rui O. Duarte RO, Moura JJG, Aureliano M. Decavanadate interactions with actin: cysteine oxidation and vanadyl formation. Dalton Trans. 2009:7985-7994.
21. Thompson KH, Orvig CJ. Design of vanadium compounds as insulin enhancing agents. J Chem Soc, Dalton Trans. 2000;2885-2892.
22. Pereira MJ, Carvalho E, Eriksson JW, Crans DC, Aureliano M. Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes. J Inorg Biochem. 2009; 103:1687-1692.
23. Nilsson J, Degerman E, Haukka M, et al. Bis-and tris(pyridyl) amine-oxidovanadium complexes: characteristics and insulin-mimetic potential. Dalton Trans. 2009:7902-7911.
24. Shechter Y, Eldberg G, Shisheva A, et al. In: Tracey AS, Crans DC, editors. Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications. Washington, DC: American Chemical Society; 1998;vol. 711:308-315.
25. Cazarolli LH, Zanatta L, Jorge AP, et al. Follow-up studies on glycosylated flavonoids and their complexes with vanadium: their anti-hyperglycemic potential role in diabetes. Chem Biol Interact. 2006; 163:177-191.
26. Huyer G, Liu S, Kelly J, et al. Mechanism of inhibition of proteintyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 1997; 272(2):843-851.
27. Posner BI, Faure R, Burgess JW, et al. Peroxovanadium compounds. A new class of potent phospho-tyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem. 1994;269:4596-4604.
28. Crans DC. In: Tracey AS, Crans DC, editors. Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications. Washington, DC: American Chemical Society; 1998; vol. 711:82-103.
29. Cuncic C, Detich N, Ethier D, Tracey AS, Gresser MJ, Ramachandran CJ. Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells: modulation by redox state. J Biol Inorg Chem. 1999;4: 354-359.
30. Tracey AS. Hydroxamido vanadates: aqueous chemistry and function in protein tyrosine phosphatases and cell cultures. J Inorg Biochem. 2000;80:11-16.
31. Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem. 2000;80:21-25
32. Li J, Guo SJ, Su H, Han LJ, Shi DY. Total synthesis of bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane as potent PTP1B inhibitor. Chin Chem Lett. 2008;19(11):1290-1292.
33. Li M, Ding W, Baruah B, Crans DC, Wang R. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato) oxovanadium (IV). J Inorg Biochem. 2008;102:1846-1853.
34. Seale AP, de Jesus LA, Kim S-Y, et al. Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes. Biotech Lett. 2005;27:221-225.
35. Scior T, Mack H-G, Guevara-Garcia JA, Koch W. Antidiabetic bis-maltolato-oxovanadium(IV): conversion of inactive trans-to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des Devel Ther. 2008;2:221-231. ISSN: 1177-8881. Available from: http://www.dovepress.com/articles.php?article_id=2591&l=Ul4dFWz2XRKpTIGDfXLJNycV27174.
36. Kiersztan A, Jarzyna R. Inhibitory effect of vanadium compounds on glutamate dehydrogenase activity in mitochondria and hepatocytes isolated from rabbit liver. Pharmacol Toxicol. 1998;82(4):167-172.
37. Brichard SM, Okitolonda W, Henquin JC. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinol. 1988;123:2048-2053.
38. Edel AL, Kopilas M, Clark TA, et al. Short-term bioaccumulation of vanadium when ingested with a tea decoction in streptozotocin-induced diabetic rats. Metab Clin Exp. 2006;55:263-270.
39. Adachi Y, Yoshikawa Y, Yoshida J, et al. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato) oxovanadium(IV) complex. Biochem Biophys Res Comm. 2006;345: 945-950.
40. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab. 1995;80:3311-3320.
41. Shechter Y, Goldwaser I. Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord Chem Rev. 2003; 237:13-22.
42. Yamaguchi M, Wakasugi K, Saito R, et al. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities. J Inorg Biochem. 2006;100:260-269.
43. Zhang Y, Yang X-D, Wang K, Crans DC. The permeability and cytotoxicity of insulin-mimetic vanadium (III, IV, V)-dipicolinate complexes. J Inorg Biochem. 2006;100:80-87.
44. Kiersztan A, Winiarska K, Drozak J, et al. Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine. Mol Cell Biochem. 2004;261:9-21.
45. Thompson KH, Chiles J, Yuen VG, Tse J, McNeill JH, Orvig C. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes. J Inorg Biochem. 200;98: 683-690.
46. Scior JT, Guevara-Garcia JA, Bernard P, Do Q-T, Domeyer D, Laufer S. Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review. Mini-Rev Med Chem. 2005;5:995-1008.
47. National Toxicology Program, National Institute of Environmental Health Sciences. Chemical information review document for oral exposure to tetravalent and pentavalent vanadium compounds. Supporting Nomination for Toxicological Evaluation by the National Toxicology Program. 2008. National Institutes of Health, U.S. Department of Health and Human Services. Research Triangle Park, NC. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/xSumPdf/NIEHS_Vanadium_compounds_508.pdf. Accessed Oct 29, 2009.
48. Facchini DM, Yuen VG, Battell ML, McNeill JH, Grynpas MD. The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone. 2006;38:368-377.
49. Caballero CNA. Master Thesis in Chemical Sciences in Spanish language: Estudio teórico de compuestos de vanadio con actividad de tipo insulina y su interacción con la enzima PTP1B. Benemérita Universidad Autónoma de Puebla, Mexico.
50. ChemOffice V5.0. CambridgeSoft, Inc. 100 CambridgePark, Cambridge, MA 02140: USA. Available from: http://www.camsoft.com.
51. Frisch MJ, et al. Gaussian 03, Revision B04. Gaussian Inc, Wallingford, CT; 2004.
52. Dennington II R, Keith T, Millam J, et al. GaussView, Version 3.09. Semichem, Inc. Shawnee Mission, KS; 2003.
53. Kopp J, Schwede T. The Swiss-Model repository of annotated threedimensional protein structure homology models. Nucleic Acids Res. 2004;32D:230-234.
54. Bardford D, Flint AJ, Tonks NK. Crystal structure of human protein tyrosine phosphatase 1B. Science. 1994;263:1397-1404.
55. SYBYL, Tripos Inc. 1699 South Hanley Road, St. Louis, Missouri, 63144, USA.
56. MOE (The Molecular Operating Environment), Version 2006.08, software. Chemical Computing Group Inc. 1010 Sherbrooke, Street West, Suite 910, Montreal, Canada; 2006.
57. HyperChem(TM) Professional 7.51, Hypercube, Inc. 1115 NW 4th Street, Gainesville, Florida 32601, USA.
58. Marvin, version: 5.1.3, 2008. ChemAxon. Available from: http://www.chemaxon.com.
59. Coupez B, Lewis RA. Docking and scoring -theoretically easy, practically impossible? Curr Med Chem. 2006;13(25):2995-3003.
60. Cavasotto CN, Orry AJW, Abagyan RA. The challenge of considering receptor flexibility in ligand docking and virtual screening. Curr Computer-Aided Drug Design. 2005;1(4):423-440.
61. Mohan V, Gibbs AC, Cummings MD, Jaeger EP, DesJarlais RL. Docking: successes and challenges. Current Pharmaceutical Design. 2005; 11(3):323-333.
62. Prandtl W, Hess LZ. Allg Anorg Chem. 1913;82-103.
63. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16(1):35-39.
64. Organization for Economic Co-operation and Development. OECD Guidelines for the Testing of Chemicals. Guideline 425 Acute Oral Toxicity -Up-and-Down Procedure, OECD, Paris; 1998.
65. The AOT425StatPgm program. Available from: http://www.epa.gov/oppfead1/harmonization.Accessed Oct 29, 2009.
66. Krosniak M, Zachwieja Z, Filipek B, Zygmunt M, Grybos R. Effect of oxovanadium(IV) complexes on nondiabetic and streptozotocin-diabetic rats. Arch Pharm Med Chem. 2001;334:388-392.
67. SAS Institute Inc. SAS/STAT User's Guide. Version 6, Cary, NC, USA; 1990.
68. BMDP Statistics Software, Inc. BMDP Statistical Software Manual. Dixon WJ, Chief editor. Berkeley, CA, USA: University of California Press; 1990.
69. Jennings WB, Farrell BM, Malone JF. Attractive intramolecular edgeto-face aromatic interactions in flexible organic molecules. Acc Chem Res. 2001;34:885-894.
70. Gung BW, Xue X, Zou Y. Enthalpy (deltaH) and entropy (deltaS) for p-stacking interactions in near-sandwich configurations: the relative importance of electrostatic, dispersive, and charge-transfer effects. J Org Chem. 2007;72(7):2469-2475.
71. Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed. 2003;42(11):1210-1250.
72. McGaughey GB, Gagné M, Rappé AK. pi-satking interactions. Alive and well in proteins. J Biol Chem. 1998;273(25):15458-15463.
73. Scrutton NS, Raine ARC. Cation-p bonding and amino-aromatic interactions in the biomolecular recognition of substituted ammonium ligands. Biochem J. 1996;319:1-8.
74. Crans DC, Yang L. Aqueous chemistry of ammonium (dipicolinato) oxovanadate(V): the first organic vanadium(V) insulin-mimetic compound. Inorg Chem. 2000;39:4409-4416.
75. Caravan P, Gelmini L. Reaction chemistry of BMOV, bis(maltolato) oxovanadium(IV) -a potent insulin mimetic agent. J Am Chem Soc. 1995;117:12759-12770.
76. Ida M, Imai K, Hashimoto S, Kawashima H. Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes. Biochem Pharmacol. 1996;51:1061-1067.
77. Posner BI. Eur Pat Appl. 1988;264-278.
78. Orvig C, McNeill JH. US Patent. 6,287,586. 2001.
79. Orvig C, McNeill JH, Melchior M. US Patent. 6,268,357. 2001.
80. Makamoto K, Shintaro I, Hidehiro Y, Hiroshi S. Japan Patent. 1990;2292217A2.
81. Olarte AZ, Carpene C, Delmas GE-T, et al. PCT Int Appl. 2002;WO 02/38152.
82. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem. 2009;103:554-558.
83. Mukherjee R, Donnay EG, Radomski MA, et al. Vanadium-vitamin B12 bioconjugates as potential therapeutics for treating diabetes. Chem Comm. 2008:3783-3785.
84. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. QJM. 2008;101:351-358.
85. Lu B, Ennis D, Lai R, Bogdanovic E. Enhanced sensitivity of insulinresistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). J Biol Chem. 2001;276:35589-35598.
86. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem. 2000;275:41439-41446.
87. Fantus IG, George R, Tang S, Chong P, Poznansky MJ. The insulinmimetic agent vanadate promotes receptor endocytosis and inhibits intracellular ligand-receptor degradation by a mechanism distinct from the lysosomotropic agents. Diabetes. 1996;45:1084-1093.
88. Stone RL, Dixon JE. Protein-tyrosine phosphatase. J Biol Chem. 1994;269:31323-31326.